A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
about
Studies on anticancer activities of antimicrobial peptidesInhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.NP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces speciesCharacterization of siamycin I, a human immunodeficiency virus fusion inhibitorRole of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target.CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection.Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activityPreclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastasesThe therapeutic potential of CXCR4 antagonists in the treatment of HIV.The intricate role of CXCR4 in cancer.Retrocyclins and their activity against HIV-1.The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.Peptide antimicrobial agents.Composite Membranes of Recombinant Silkworm Antimicrobial Peptide and Poly (L-lactic Acid) (PLLA) for biomedical application.Multimodality imaging of CXCR4 in cancer: current status towards clinical translation.Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.Recent patents regarding the discovery of small molecule CXCR4 antagonists.Synthesis and Evaluation of [(67)Ga]-AMD3100: A Novel Imaging Agent for Targeting the Chemokine Receptor CXCR4.Role of CXCR4 in HIV infection and its potential as a therapeutic target.Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.Peptide and peptidomimetic ligands for CXC chemokine receptor 4 (CXCR4).Imaging agents for the chemokine receptor 4 (CXCR4).A future perspective on the development of chemokine receptor CXCR4 antagonists.Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.The proteome targets of intracellular targeting antimicrobial peptides.Molecular imaging probes derived from natural peptides.Rational design of CXCR4 specific antibodies with elongated CDRs.PET imaging of CXCR4 receptors in cancer by a new optimized ligand.Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine-rich antimicrobial peptides.Peptides: Production, bioactivity, functionality, and applications.Antimicrobial Peptides: Diversity, Mechanism of Action and Strategies to Improve the Activity and Biocompatibility In Vivo.Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity.Synthesis and properties of cyclic gomesin and analogues.Entry and fusion inhibitors of HIV
P2860
Q24650885-971B35B2-7DD3-45D1-A071-C7FCD415399AQ28343496-C92C423D-6468-4AC3-AB47-4E2AA2A13A42Q28378834-E869641B-F30C-4BD0-9F63-4714D122CF3BQ28379084-EC5087CC-9603-4A57-B8BB-455117201DE0Q33559560-14FC5E1F-4E50-48C1-8B68-4BF578568E93Q33677057-DCADDD10-86A3-4E1E-9D49-714CF0231098Q33996826-EEBB0048-5245-42C7-A6CD-6C641E0BE06DQ34569177-50E11B9E-E380-4539-93ED-95DB5F6CCA6BQ34955359-20B13F64-2FB6-4E48-93E0-060D443241CDQ34994758-C41D5C16-C4F6-4613-BC61-1B189CB706C0Q35056053-E251D208-87C3-47D5-84F8-1DC34CAC170BQ35067624-02AD49C2-1B56-4D97-AA15-CD0ACE7751F8Q35879590-D0167E70-BB1F-4C6C-BEB3-C8931DFDA901Q36318564-12759AB8-7D74-42E8-9CC9-14A157A3DBCDQ36538861-C9596B07-E1B6-4C7B-ACB2-6ECCB3B9CB1AQ37160057-F52B90D6-49A8-4808-8AEE-879780D49496Q37337280-51F8825F-5052-48C2-B646-38B1346C3854Q37352728-1825A258-B442-406F-BC76-243A2839E024Q37481233-ACE03567-226F-4094-9BF2-EE3928019C0EQ37632872-631D05F7-4635-4FB3-BA29-494D15B2F5DEQ37772888-352CBAFE-F4FA-4FFC-93C6-3E9815C28CDBQ37866794-85A99BBA-4471-4F11-BF2F-D0A373406687Q38003847-20790082-071A-408E-B974-6E9E54F6717EQ38022430-36D6F8CA-00B4-4335-AAB8-F8F18DCD0909Q38089173-408E9C4F-ECA0-41A8-B39D-BD6AAB7DA137Q38539666-25560052-6FD7-415F-8201-38DBC578D758Q38663372-2C3BE773-1E31-4239-83DC-003E307E5D2CQ38748846-B35D99C2-634B-4512-877B-96586CE09D70Q38973911-B72CE59B-71C7-4D90-A7EB-81DB7C9C40FFQ39502623-29E00319-F14B-4A0D-A368-CE13E3C696DCQ41307316-2A6B1F93-D809-4E21-9BA8-6EB4832D1E96Q47666763-5AC2D813-10E3-41C8-955D-4DB95D3A59D2Q47723258-F85D129F-7596-40EB-BB52-FF2768F6E222Q54263518-34F8E740-898D-4B05-9029-E6A656269308Q54330884-5681E61B-AB57-4529-883F-A41C2F4603E5Q58389047-6BAE4D14-9CD9-4E5D-B1B0-49238EAE7C3F
P2860
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
description
1992 nî lūn-bûn
@nan
1992 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@ast
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@en
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@nl
type
label
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@ast
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@en
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@nl
prefLabel
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@ast
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@en
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@nl
P2093
P1476
A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)
@en
P2093
H Nakashima
H Tamamura
T Murakami
Y Terakawa
P304
P356
10.1016/0006-291X(92)92280-B
P407
P577
1992-12-15T00:00:00Z